Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DarioHealthDRIO -6.58%61 Debt-to-EBITDA is -1.22 as of Mar. 2026. GuruFocus rates DRIO with a GF Score™ of 61/100 and a GF Value™ of $6.90 (Fairly Valued). The stock has 4 warning signs investors should review. Among 478 Healthcare Providers & Services companies, DarioHealth ranks worse than 209204.81% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for DarioHealth's Debt-to-EBITDA or its related term are showing as below:
DRIO'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.03 Med: -0.5 Max: 0
Current: -1.03
DRIO's Debt-to-EBITDA is ranked worse than 100% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.22
vs DRIO: -1.03
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
DarioHealth Debt-to-EBITDA Related Terms
DarioHealth Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for DarioHealth's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, DarioHealth's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DarioHealth Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DarioHealth's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where DarioHealth's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
DarioHealth (DRIO) has a Debt-to-EBITDA of -1.22 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on DarioHealth. According to the industry distribution chart, DarioHealth ranks #999999 out of 478 companies in the Healthcare Providers & Services industry.
Is DarioHealth's Debt-to-EBITDA too high?
DarioHealth's current Debt-to-EBITDA is -1.22. Based on the distribution chart, DarioHealth ranks #999999 out of 478 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, DarioHealth has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DarioHealth's Debt-to-EBITDA compare to ONMD and DH?
According to the Healthcare Providers & Services industry distribution chart, DarioHealth ranks #999999 out of 478 companies for Debt-to-EBITDA. This places DarioHealth in the lower half of its industry. The industry median Debt-to-EBITDA is 2.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on DarioHealth. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DarioHealth's current Debt-to-EBITDA is -1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DarioHealth stock overvalued right now?
Based on GuruFocus' analysis, DarioHealth (DRIO) is currently considered Fairly Valued. The stock's GF Value™ is $6.90, compared to a current price of $7.10 — trading 2.9% above its estimated fair value. The current Debt-to-EBITDA is -1.22. DarioHealth's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For DarioHealth (DRIO), the current Debt-to-EBITDA is -1.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DarioHealth (DRIO) Overvalued in 2026?
Based on GuruFocus' analysis, DarioHealth stock appears to be overvalued.
The current stock price of $7.10 is trading 2.9% above its estimated GF Value™ of $6.90.
GuruFocus considers DarioHealth to be Fairly Valued.
Key valuation signals for DRIO:
Debt-to-EBITDA: -1.22
GF Value™: $6.90 vs. price of $7.10 (2.9% above fair value)
No single metric tells the full story. See the DRIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
61GF Score
Get the complete analysis for DRIO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRIO has been successfully added to your 
